FGFR3
Fibroblast growth factor receptor 3
As of the edition of 20 October 2026, FGFR3 (fibroblast growth factor receptor 3, UniProt P22607) has 24 drugs tested at it and 26 companies on the list, 9 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P22607
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 16
- Disease areas
- Cancer; Lungs and airways; Digestive system; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Immune system; Hormones
- Registered trials of its drugs
- 523
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 5 |
| Went quiet | 4 |
| Stopped | 8 |
| Status not established | 1 |
| Total | 24 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nintedanib | Marketed | Phase 4 | Ends 2027 |
| Dovitinib | Active | Phase 3 | none listed |
| Pemigatinib | Marketed | Phase 3 | Ends 2040 |
| Erdafitinib | Marketed | Phase 3 | Ends 2033 |
| Masitinib | Stopped | Phase 3 | none listed |
| Infigratinib | Marketed | Phase 3 | Ends 2029 |
| Futibatinib | Marketed | Phase 3 | Ends 2036 |
| Fexagratinib | Active | Phase 3 | none listed |
| Brivanib | Stopped | Phase 3 | none listed |
| Rogaratinib | Stopped | Phase 3 | none listed |
| XL-999 | Went quiet | Phase 2 | none listed |
| ENMD-981693 | Went quiet | Phase 2 | none listed |
12 of 24 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 9 |
| Route B | 6 |
| Engaged | 7 |
| Undetermined | 4 |
| Total on the list | 26 |
| Company | Route |
|---|---|
| Incyte | Route B |
| AstraZeneca | Route A |
| Roche | Route A |
The other 23 companies at FGFR3
In the product26 companies in all; 23 are not named here, and no score is.
See the 26 companies at FGFR3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.